Here are Wednesday's biggest analyst calls: Nvidia, SpaceX, Apple, Tesla, Marvell, Flutter, Micron & more

Wall Street research was broadly positive, with multiple upgrades and new Buy or Outperform ratings across sectors; KBW also downgraded PJT to Market Perform while upgrading Moelis to Outperform. Cantor Fitzgerald raised Humana's price target to $460 from $300 and increased its 2027 and 2028 EPS estimates to $17.96 and $28.27, respectively. DA Davidson raised its Micron price target to $3,000 from $2,100, while UBS lifted Tesla's target to $391 from $385 and reiterated Neutral.

Analysis

This is a broker-sentiment batch, not a new information set: the immediate effect is likely stock-specific positioning and short-covering, while the 1–3 month test is whether estimates, guidance, or operating data follow. Avoid treating price targets as evidence of upside; repeated “buy the weakness” framing can signal crowded dip-buying rather than a durable catalyst. The clearest relative-value signal is Moelis versus PJT: if sub-$10B transaction activity converts into completed mandates, Moelis could see better near-term fee momentum while PJT faces relative disappointment. That thesis is conditional on public pipeline and completion data, not established by the rating changes alone. For Marvell, the key second-order issue is whether connectivity growth offsets custom-accelerator customer/program concentration; investor-day confidence does not itself remove execution or bargaining-power risk. Humana’s revised out-year estimates warrant attention, but policy/pricing and medical-cost outcomes can overwhelm a valuation-led rebound. Across the broader list, no trade is justified solely by analyst upgrades; the sentiment skew is positive, but the supplied impact is modest. Over 6–18 months, only realized earnings, cash generation, or structural share gains should support multiple expansion. Falsifiers include weakening deal completions for Moelis, renewed program/customer concentration concerns at Marvell, or adverse Medicare Advantage pricing and cost trends at Humana.

Key Decisions for Investors

• Consider a small, catalyst-driven MC long / PJT short relative-value position rather than a broad financials trade. Add only if subsequent pipeline/completion data supports divergence; cut if deal activity weakens broadly or PJT execution improves relative to Moelis.
• Keep MRVL on a verification watch, not an upgrade-chasing buy: check next guidance and disclosures for connectivity growth, custom-program concentration, and margin mix. Reassess if growth depends on a narrow set of programs or margin performance disappoints.
• Treat HUM as a policy-and-cost watch item. Require confirmation in Medicare Advantage pricing, membership economics, and medical-cost trends before underwriting the higher out-year earnings path; adverse rate or cost updates would falsify the rebound thesis.
• Do not buy the entire upgrade list. For IVZ, NEXA, XPO, and other cyclically exposed names, wait for estimate revisions or operating data that validate the call; reassess any initial price pop if it is not followed by improved guidance.